1. Home
  2. PMCB

as of 12-05-2025 3:46pm EST

$1.16
$0.03
-2.51%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.

Chart Type:
Time Range:
Founded: 1996 Country:
United States
United States
Employees: N/A City: LAS VEGAS
Market Cap: 5.3M IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 9.5M
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: 0.01 EPS Growth: -98.82
52 Week Low/High: $0.63 - $1.90 Next Earning Date: 12-15-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

AI-Powered PMCB Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 3 days ago

AI Recommendation

hold
Model Accuracy: 64.19%
64.19%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest PharmaCyte Biotech Inc. News

PMCB Breaking Stock News: Dive into PMCB Ticker-Specific Updates for Smart Investing

All PMCB News

Share on Social Networks: